A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin

Frontiers in Medicine

Volumn 2, Issue MAR, 2015, Pages 19-

  Mavani, Gaurang P ^a   DeVita, Maria V ^a   Michelis, Michael F ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

Arginine vasopressin; Cell proliferation; Chronic kidney disease; Hypertension; Inflammation; Metabolic syndrome; Osteopenia; Social behavior

Indexed keywords

EID: 84973576386     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00019     Document Type: Review

References (62)

1. Robertson GL. The regulation of vasopressin functions in health and disease. Recent Prog Horm Res (1975) 33:333-85.
2. Andersen LJ, Andersen JL, Schutten HJ, Warberg J, Bie P. Antidiuretic effect of subnormal levels of arginine vasopressin in normal humans. Am J Physiol (1990) 259(1 Pt 2):R53-60.
3. Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev (2012) 92(4):1813-64. doi: 10.1152/physrev.00035.2011
4. Luttinger D, Hernandez DE, Nemeroff CB, Prange AJ Jr. Peptides and nociception. Int Rev Neurobiol (1984) 25:185-241. doi:10.1016/S0074-7742(08)60680-7
5. Bodnar RJ, Wallace MM, Kordower JH, Nilaver G, Cort J, Zimmerman EA. Modulation of nociceptive thresholds by vasopressin in the Brattleboro and normal rat. Ann N Y Acad Sci (1982) 394(1):735-9. doi:10.1111/j.1749-6632.1982.tb37491.x
6. Ahn DK, Kim KH, Ju JS, Kwon S, Park JS. Microinjection of arginine vasopressin into the central nucleus of amygdala suppressed nociceptive jaw opening reflex in freely moving rats. Brain Res Bull (2001) 55(1):117-21. doi:10.1016/S0361-9230(01)00493-2
7. Watkins LR, Suberg SN, Thurston CL, Culhane ES. Role of spinal cord neuropeptides in pain sensitivity and analgesia: thyrotropin releasing hormone and vasopressin. Brain Res (1986) 362(2):308-17. doi:10.1016/0006-8993(86)90455-5
8. Yang J, Lu L, Wang HC, Zhan HQ, Hai GF, Pan YJ, et al. Effect of intranasal arginine vasopressin on human headache. Peptides (2012) 38(1):100-4. doi:10.1016/j.peptides.2012.07.029
9. Tamma R, Sun L, Cuscito C, Lu P, Corcelli M, Li J, et al. Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc Natl Acad Sci U S A (2013) 110(46):18644-9. doi:10.1073/pnas.1318257110
10. Sejling A, Pedersen-Bjergaard U, Eiken P. Syndrome of inappropriate ADH secretion and severe osteoporosis. J Clin Endocrinol Metab (2012) 97(12):4306-10. doi:10.1210/jc.2012-2031
11. Barsony J, Sugimura Y, Verbalis JG. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem (2011) 286(12):10864-75. doi:10.1074/jbc.M110.155002
12. Hew-Butler T, Stuempfle KJ, Hoffman MD. Bone: an acute buffer of plasma sodium during exhaustive exercise? Horm Metab Res (2013) 45(10):697-700. doi:10.1055/s-0033-1347263
13. Sandhu HS, Gilles E, DeVIta MV, Panagopoulos G, Michelis MF. Hyponatremia associated with large-bone fracture in elderly patients. Int Urol Nephrol (2009) 41(3):733-7. doi:10.1007/s11255-009-9585-2
14. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab (2009) 94(7):2558-64. doi:10.1210/jc.2008-2278
15. Pasquali R, Gagliardi L, Vicennati V, Gambineri A, Colitta D, Ceroni L, et al. ACTH and cortisol response to combined corticotropin releasing hormone-arginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome. Int J Obes Relat Metab Disord (1999) 23(4):419-24. doi:10.1038/sj.ijo.0800838
16. Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation (2010) 121(19):2102-8. doi:10.1161/CIRCULATIONAHA.109.909663
17. Enhörning S, Leosdottir M, Wallström P, Gullberg B, Berglund G, Wirfält E, et al. Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am J Clin Nutr (2009) 89(1):400-6. doi:10.3945/ajcn.2008.26382
18. Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, et al. Low water intake and risk for new-onset hyperglycemia. Diabetes Care (2011) 34(12):2551-4. doi:10.2337/dc11-0652
19. Yibchok-anun S, Abu-Basha EA, Yao CY, Panichkriangkrai W, Hsu WH. The role of arginine vasopressin in diabetes-associated increase in glucagon secretion. Regul Pept (2004) 122(3):157-62. doi:10.1016/j.regpep.2004.06.010
20. Dheen ST, Tay SS, Wong WC. Arginine vasopressin and oxytocin-likes immunoreactive neurons in the hypothalamic paraventricular and supraoptic nuclei of streptozotocin-induced diabetic rats. Arch Histol Cytol (1994) 57(5):461-72. doi:10.1679/aohc.57.461
21. Havel RJ, Goldfien A. The role of the sympathetic nervous system in the metabolism of free fatty acids. J Lipid Res (1959) 1(1):102-8.
22. Hiroyama M, Aoyagi T, Fujiwara Y, Birumachi J, Shigematsu Y, Kiwaki K, et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol Endocrinol (2007) 21(1):247-58. doi:10.1210/me.2006-0069
23. Okuno A, Yamamato M, Itoh S. Lowering of the body temperature induced by vasopressin. Jpn J Physiol (1965) 15(4):378-87. doi:10.2170/jjphysiol.15.378
24. Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi JI, Yamauchi J, et al. Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol (2007) 584(1):235-44. doi:10.1113/jphysiol.2007.136481
25. Gavras H, Hatzinikolaou P, North W, Bresnahan M, Gavras I. Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. Hypertension (1982) 4(3):400-5. doi:10.1161/01.HYP.4.3.400
26. Landry DW, Levin HR, Gallant EM, Ashton RC, Seo S, D'Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation (1997) 95(5):1122-5. doi:10.1161/01.CIR.95.5.1122
27. Bankir L, Perucca J, Weinberger MH. Ethnic differences in urine concentration: possible relationship to blood pressure. Clin J Am Soc Nephrol (2007) 2(2):304-12. doi:10.2215/CJN.03401006
28. Choukroun G, Schmitt F, Martinez F, Drüeke TB, Bankir L. Low urine flow reduces the capacity to excrete a sodium load in humans. Am J Physiol (1997) 273(5):R1726-33.
29. Nicco C, Wittner M, DiStefano A, Jounier S, Bankir L, Bouby N. Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension (2001) 38(5):1143-9. doi:10.1161/hy1001.092641
30. Möhring J, Glänzer K, Maciel JA Jr, Däsing R, Kramer HJ, Arbogast R, et al. Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmacol (1980) 2(4):367-76. doi:10.1097/00005344-198007000-00004
31. Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol (2013) 9(4):223-39. doi:10.1038/nrneph.2013.22
32. Stack AG, Murthy BV. Cigarette use and cardiovascular risk in chronic kidney disease: an unappreciated modifiable lifestyle risk factor. Semin Dial (2010) 23(3):298-305. doi:10.1111/j.1525-139X.2010.00728.x
33. Schaeffner E, Ritz E. Alcohol and kidney damage: a Janus-faced relationship. Kidney Int (2012) 81(9):816-8. doi:10.1038/ki.2012.14
34. Torres VE. Vasopressin in chronic kidney disease: an elephant in the room? Kidney Int (2009) 76(9):925-8. doi:10.1038/ki.2009.325
35. Bardoux P, Martin H, Ahloulay M, Schmitt F, Bouby N, Trinh-Trang-Tan MM, et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci U S A (1999) (18):10397-402. doi:10.1073/pnas.96.18.10397
36. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant (2003) 18(9):1755-63. doi:10.1093/ndt/gfg277
37. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant (2003) 18(3):497-506. doi:10.1093/ndt/18.3.497
38. Kuro-o M. Klotho. Pflügers Arch (2010) 459(2):333-43. doi:10.1007/s00424-009-0722-7
39. Ohnishi M, Razzaque MS. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J (2010) 24(9):3562-71. doi:10.1096/fj.09-152488
40. Tang C, Pathare G, Michael D, Fajol A, Eichenmüller M, Lang F. Downregulation of klotho expression by dehydration. Am J Physiol Renal Physiol (2011) 301(4):F745-50. doi:10.1152/ajprenal.00037.2011
41. Egashira N, Mishima K, Iwasaki K, Oishi R, Fujiwara M. New topics in vasopressin receptors and approach to novel drugs: role of the vasopressin receptor in psychological and cognitive functions. J Pharmacol Sci (2009) 109(1):44-9. doi:10.1254/jphs.08R14FM
42. Heinrichs M, von Dawans B, Domes G. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol (2009) 30(4):548-57. doi:10.1016/j.yfrne.2009.05.005
43. Keverne EB, Curley JP. Vasopressin, oxytocin and social behaviour. Curr Opin Neurobiol (2004) 14(6):777-83. doi:10.1016/j.conb.2004.10.006
44. Ganio MS, Armstrong LE, Casa DJ, McDermott BP, Lee EC, Yamamoto LM, et al. Mild dehydration impairs cognitive performance and mood of men. Br J Nutr (2011) 106(10):1535-43. doi:10.1017/S0007114511002005
45. Spigt MG, Kuijper EC, Schayck CP, Troost J, Knipschild PG, Linssen VM, et al. Increasing the daily water intake for the prophylactic treatment of headache: a pilot trial. Eur J Neurol (2005) 12(9):715-8. doi:10.1111/j.1468-1331.2005.01081.x
46. Wilson MG, Morley JE. Impaired cognitive function and mental performance in mild dehydration. Eur J Clin Nutr (2003) 57:S24-9. doi:10.1038/sj.ejcn.1601898
47. Thibonnier M, Plesnicher CL, Berrada K, Berti-Mattera L. Role of the human V1 vasopressin receptor COOH terminus in internalization and mitogenic signal transduction. Am J Physiol Endocrinol Metab (2001) 281(1):E81-92.
48. Chiu T, Wu SS, Santiskulvong C, Tangkijvanich P, Yee HF Jr, Rozengurt E. Vasopressin-mediated mitogenic signaling in intestinal epithelial cells. Am J Physiol Cell Physiol (2002) 282(3):C434-50. doi:10.1152/ajpcell.00240.2001
49. Ghosh PM, Mikhailova M, Bedolla R, Kreisberg JI. Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. Am J Physiol Renal Physiol (2001) (6):F972-9.
50. Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M. Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells. Pharmacol Res (2008) 57(2):142-50. doi:10.1016/j.phrs.2008.01.003
51. MacKinnon AC, Tufail-Hanif U, Wheatley M, Rossi AG, Haslett C, Seckl M, et al. Targeting V1A-vasopressin receptors with [Arg6, D-Trp7, 9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies. Br J Pharmacol (2009) 156(1):36-47. doi:10.1111/j.1476-5381.2008.00003.x
52. Baker C, Richards LJ, Dayan CM, Jessop DS. Corticotropin-releasing hormone immunoreactivity in human T and B cells and macrophages: colocalization with arginine vasopressin. J Neuroendocrinol (2003) 15(11):1070-4. doi:10.1046/j.1365-2826.2003.01099.x
53. Park SJ, Shin JI. Inflammation and hyponatremia: an underrecognized condition? Korean J Pediatr (2013) 56(12):519-22. doi:10.3345/kjp.2013.56.12.519
54. Boyd JH, Holmes CL, Wang Y, Roberts H, Walley KR. Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. Resuscitation (2008) 79(2):325-31. doi:10.1016/j.resuscitation.2008.07.006
55. Chikanza IC, Grossman AS. Hypothalamic-pituitary-mediated immunomodulation: arginine vasopressin is a neuroendocrine immune mediator. Rheumatology (1998) 37(2):131-6. doi:10.1093/rheumatology/37.2.131
56. Chassin C, Tourneur E, Bens M, Vandewalle A. A role for collecting duct epithelial cells in renal antibacterial defences. Cell Microbiol (2011) 13(8):1107-13. doi:10.1111/j.1462-5822.2011.01614.x
57. Chassin C, Hornef MW, Bens M, Lotz M, Goujon JM, Vimont S, et al. Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin. J Exp Med (2007) 204(12):2837-52. doi:10.1084/jem.20071032
58. Franchini M. The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol (2007) 82(8):731-5. doi:10.1002/ajh.20940
59. Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest (2000) 106(1):107-16. doi:10.1172/JCI9516
60. Guillon G, Grazzini E, Andrez M, Breton C, Trueba M, Gal CSL, et al. Vasopressin: a potent autocrine/paracrine regulator of mammal adrenal functions. Endocr Res (1998) 24(3-4):703-10. doi:10.3109/07435809809032672
61. Gallo-Payet N, Guillon G. Regulation of adrenocortical function by vasopressin. Horm Metab Res (1998) 30(06/07):360-7. doi:10.1055/s-2007-978899
62. Horiba N, Suda T, Aiba M, Naruse M, Nomura K, Imamura M, et al. Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab (1995) 80(8):2336-41. doi:10.1210/jc.80.8.2336